An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors

Disease Sites:

Breast, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I, Uterine

Staging:

Phase I/II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

SMP-3124LP

Principal Investigator(s):

Eng, Cathy

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

05-20-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTPHI23348

National Clinical Trial ID:

NCT06526819

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available